Adult Clinical Trial Safety Profile | DUPIXENT® (dupilumab)

The 52-week safety profile of DUPIXENT + TCS in adults was generally consistent
with the Week 16 adult safety profile¹

Adverse reactions occurring in ≥1% of adult patients through Week 16¹

Adverse reaction	DUPIXENT 300 mg Q2W monotherapy^a		DUPIXENT 300 mg Q2W + TCS^b
Adverse reaction	DUPIXENT^c (n=529) %	PLACEBO (n=517) %	DUPIXENT + TCS^c (n=110) %	PLACEBO + TCS (n=315) %
Injection site reaction	10%	5%	10%	6%
Conjunctivitis^d	10%	2%	9%	5%
Blepharitis	<1%	<1%	5%	1%
Oral herpes	4%	2%	3%	2%
Keratitis^e	<1%	0%	4%	0%
Eye pruritus	1%	<1%	2%	1%
Oral herpes simplex virus infection^f	2%	1%	1%	<1%
Dry eye	<1%	0%	2%	<1%

DUPIXENT 300 mg
Q2W monotherapy^a

Injection site reaction
	DUPIXENT^c (n=529) %	10%
	Placebo (n=517) %	5%

Conjunctivitis^d
	DUPIXENT^c (n=529) %	10%
	Placebo (n=517) %	2%

Blepharitis
	DUPIXENT^c (n=529) %	<1%
	Placebo (n=517) %	<1%

Oral herpes
	DUPIXENT^c (n=529) %	4%
	Placebo (n=517) %	2%

Keratitis^e
	DUPIXENT^c (n=529) %	<1%
	Placebo (n=517) %	0%

Eye pruritus
	DUPIXENT^c (n=529) %	1%
	Placebo (n=517) %	<1%

Oral herpes simplex virus infection^f
	DUPIXENT^c (n=529) %	2%
	Placebo (n=517) %	1%

Dry eye
	DUPIXENT^c (n=529) %	<1%
	Placebo (n=517) %	0%

DUPIXENT 300 mg
Q2W + TCS^b

Injection site reaction
	DUPIXENT + TCS^c (n=110) %	10%
	Placebo + TCS (n=315) %	6%

Conjunctivitis^d
	DUPIXENT + TCS^c (n=110) %	9%
	Placebo + TCS (n=315) %	5%

Blepharitis
	DUPIXENT + TCS^c (n=110) %	5%
	Placebo + TCS (n=315) %	1%

Oral herpes
	DUPIXENT + TCS^c (n=110) %	3%
	Placebo + TCS (n=315) %	2%

Keratitis^e
	DUPIXENT + TCS^c (n=110) %	4%
	Placebo + TCS (n=315) %	0%

Eye pruritus
	DUPIXENT + TCS^c (n=110) %	2%
	Placebo + TCS (n=315) %	1%

Oral herpes simplex virus infection^f
	DUPIXENT + TCS^c (n=110) %	1%
	Placebo + TCS (n=315) %	<1%

Dry eye
	DUPIXENT + TCS^c (n=110) %	2%
	Placebo + TCS (n=315) %	<1%

Treatment-emergent eosinophilia (≥5,000 cells/mcL) was reported in¹:

<3% of DUPIXENT-treated subjects and <0.5% of placebo-treated subjects (SOLO 1, SOLO 2, and AD-1021; DRI12544, QUEST, and VOYAGE; SINUS-24 and SINUS-52; PRIME and PRIME2)^g
8% of DUPIXENT-treated subjects and 0% of placebo-treated subjects (AD-1539)

^aPooled analysis of SOLO 1, SOLO 2, and AD-1021 (phase 2 dose-ranging study).¹

^bAnalysis of CHRONOS in which subjects were on background TCS therapy.¹

^cDUPIXENT 600 mg at Week 0, followed by 300 mg every 2 weeks.¹

^dConjunctivitis cluster includes conjunctivitis, allergic conjunctivitis, bacterial conjunctivitis, viral conjunctivitis, giant papillary conjunctivitis, eye irritation, and eye inflammation.

^eKeratitis cluster includes keratitis, ulcerative keratitis, allergic keratitis, atopic keratoconjunctivitis, and ophthalmic herpes simplex.¹

^fOther herpes simplex virus infection cluster includes herpes simplex, genital herpes, herpes simplex otitis externa, and herpes virus infection, but excludes eczema herpeticum.¹

^gDRI12544, QUEST, and VOYAGE are part of the asthma clinical trial program; SINUS-24 and SINUS-52 are part of the chronic rhinosinusitis with nasal polyposis clinical trial program; PRIME and PRIME2 are part of the prurigo nodularis clinical trial program.¹

Select adverse events in the 52-week trial in adults

The rate of serious adverse events with DUPIXENT + TCS was comparable to placebo + TCS (4% vs 5%, respectively)²
Keratitis was reported in 4% of the DUPIXENT + TCS group and in 0% of the placebo + TCS group¹
Conjunctivitis was reported in 16% of the DUPIXENT + TCS group and in 9% of the placebo group + TCS group¹
Most patients experiencing conjunctivitis recovered or were recovering during the treatment period¹

Numerically fewer patients treated with DUPIXENT developed skin infections
compared with placebo^2,h

10.9% vs 17.8% of adults in CHRONOS, respectively

^hData reflect adjudicated nonherpetic skin infections through Week 52.

Discontinuation rates in adults due to adverse events with DUPIXENT
with or without TCS were comparable to those with placebo¹

1.9% of patients treated with DUPIXENT discontinued treatment through Week 16 vs 1.9% of patients treated with placebo through Week 16 (SOLO 1, SOLO 2, and AD-1021)
Similar discontinuation rates occurred at Week 52 in CHRONOS (1.8% with DUPIXENT + TCS vs 7.6% with placebo + TCS)

Patients should discontinue DUPIXENT if a clinically significant hypersensitivity reaction occurs or until a parasitic (helminth) infection resolves in a patient who does not respond to anti-helminth treatment.¹

Safety data collected from
three Phase 3 trials and one
dose-ranging trial (AD-1021)
(N=2304)^1,2

49% had allergic rhinitis
37% had food allergy
27% had allergic conjunctivitis

Safety and efficacy of DUPIXENT have not been established in the treatment of these conditions.¹

Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with DUPIXENT¹

Avoid use of live vaccines during treatment with DUPIXENT¹

NOT AN IMMUNOSUPPRESSANT¹

NO INITIAL LAB TESTING OR ONGOING
LAB MONITORING,
according to the
Prescribing Information¹

NO KNOWN DRUG-TO-DRUG
INTERACTIONS¹

Not metabolized through the liver or excreted
through the kidneys

NO BOXED WARNING¹

Please see additional Warnings and
Precautions in the
Prescribing Information
and Important Safety Information below.

SELECT IMPORTANT
SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information below.

IN AN OPEN-LABEL EXTENSION (OLE) CLINICAL
TRIAL IN ADULTS

LONG-TERM SAFETY PROFILE
THROUGH ≈5 YEARS WAS GENERALLY
CONSISTENT WITH AD CONTROLLED
STUDIES¹

AD-1225 Study description: The OLE safety data in this open-label extension study reflect exposure to DUPIXENT
200 mg QW, 300 mg QW, and 300 mg Q2W in 2677 subjects who had varying lengths of treatment exposure (179
subjects exposed for at least 260 weeks). In DUPIXENT clinical trials, QW dosing did not demonstrate additional
treatment benefit over Q2W dosing

QW, once weekly; Q2W, once every 2 weeks.

Dosage and administration

Thinking about prescribing DUPIXENT for atopic hand and foot dermatitis? Find the information you need to get started.

Explore ADMINISTRATION Options

Demonstrated long-term safety profile

The 52-week safety profile of DUPIXENT + TCS in adults was generally consistent
with the Week 16 adult safety profile¹

DUPIXENT 300 mg
Q2W monotherapy^a

DUPIXENT 300 mg
Q2W + TCS^b

Numerically fewer patients treated with DUPIXENT developed skin infections
compared with placebo^2,h

Discontinuation rates in adults due to adverse events with DUPIXENT
with or without TCS were comparable to those with placebo¹

Safety data collected from
three Phase 3 trials and one
dose-ranging trial (AD-1021)
(N=2304)^1,2

Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with DUPIXENT¹

Other attributes & important
considerations

Demonstrated long-term safety profile

The 52-week safety profile of DUPIXENT + TCS in adults was generally consistent with the Week 16 adult safety profile1

DUPIXENT 300 mg Q2W monotherapya

DUPIXENT 300 mg Q2W + TCSb

Numerically fewer patients treated with DUPIXENT developed skin infections compared with placebo2,h

Discontinuation rates in adults due to adverse events with DUPIXENT with or without TCS were comparable to those with placebo1

Safety data collected from three Phase 3 trials and one dose-ranging trial (AD-1021) (N=2304)1,2

Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with DUPIXENT1

Other attributes & important considerations

Are you sure you want to leave?

Are you sure you want to leave?

The 52-week safety profile of DUPIXENT + TCS in adults was generally consistent
with the Week 16 adult safety profile¹

DUPIXENT 300 mg
Q2W monotherapy^a

DUPIXENT 300 mg
Q2W + TCS^b

Numerically fewer patients treated with DUPIXENT developed skin infections
compared with placebo^2,h

Discontinuation rates in adults due to adverse events with DUPIXENT
with or without TCS were comparable to those with placebo¹

Safety data collected from
three Phase 3 trials and one
dose-ranging trial (AD-1021)
(N=2304)^1,2

Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with DUPIXENT¹

Other attributes & important
considerations